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uthor’s reply
We are grateful for the opportunity to respond to Dr. Kawada’s
etter, in which he raised two points about our article published
n the Journal of Cardiology in 2013, “Prognostic value of B-type
atriuretic peptide and its amino-terminal proBNP fragment for
ardiovascular events with stratiﬁcation by renal function”.
In this article, we evaluated the utility of B-type natriuretic pep-
ide (BNP) and its amino-terminal proBNP fragment (NT-proBNP)
s predictors for mortality and cardiovascular events in patients
ith renal dysfunction.Wealso determined equations deﬁningNT-
roBNP levels as a function of BNP levels for patients with different
tages of chronic kidney disease (CKD), because of a lack of an
quation. BNP and NT-proBNP are important biomarkers for the
iagnosis and assessment of severity of cardiac failure and for pre-
icting theprognosis of theaffectedpatients. Thebiologically active
NP and its inactive counterpart, NT-proBNP, are produced by pro-
eolytic digestion of the common precursor hormone proBNP. So
he same molar BNP and NT-proBNP are produced biochemically.
owever, thesemolecules showdifferent blood concentration pro-
les, owing to thedifference in standardpeptidesused ineachassay
ystem, metabolic patterns, and patients’ renal function. Compar-
son of the predictive performance of these biomarkers and the
uantitative relationship between their blood levels are topics of
ngoing debate.
The ﬁrst point of Dr. Kawada’s comments relates to the areas
nder the receiver operating characteristic curves (AUC) for all-
ause deaths and the composite end point. In particular, he
uggested testing the superiority of NT-proBNP using speciﬁc soft-
are programs. In our study, NT-proBNP and BNP yielded similar
UC for patients with CKD stages 1–3. In patients with CKD stages
and 5, NT-proBNP provided larger AUCs than BNP, but the differ-
nce was not statistically signiﬁcant when tested using a method
escribed in the literature [1]. For this reason, we observed that
NT-proBNP may be superior to BNP in patients with an eGFR
30ml/min/1.73m2”. Our deﬁnite conclusion is that both BNP and
T-proBNP are useful biomarkers for all-cause mortality and car-
iovascular events. It would be unfortunate if our expression was
aken to be more deﬁnitive than was intended.rdiology 64 (2014) 241–242
Second, based on the observed close correlation between
NT-proBNP and BNP, Dr. Kawada suggested that the multivari-
ate analysis of the correlation between clinical parameters and
NT-proBNP should exclude BNP from explanatory variables and,
likewise, the multivariate analysis of the correlation between
clinical parameters and BNP should exclude NT-proBNP from
explanatory variables. It is correct that NT-proBNP and BNP lev-
els were signiﬁcantly correlated, as illustrated in Fig. 1 of our
article. Therefore, multivariate correlation analyses of NT-proBNP
excluded BNP from explanatory parameters in our report, and vice
versa. Readers may follow our procedure if they carefully examine
Tables 3 and 4, in which neither NT-proBNP nor BNP is included in
the lists of explanatory variables. We reject Dr. Kawada’s remark
as a misunderstanding on his part. The equations in the article
that deﬁned NT-proBNP levels as a function of BNP must logically
include both parameters.
We believe that our response fully addresses Dr. Kawada’s con-
cerns. We are pleased that our article drew the attention of the
medical community and stimulated further discussion.
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